Lilly wraps up Sigilon Therapeutics acquisition to amplify Type 1 diabetes research
Eli Lilly and Company (Lilly) has formally announced the culmination of its $309.6 million takeover of biopharma trailblazer, Sigilon Therapeutics, Inc. (NASDAQ: SGTX). This strategic acquisition propels Lilly’s quest to pioneer advanced encapsulated cell therapies, prominently spotlighting the SIG-002 treatment for type 1 diabetes. Driven by its mission to “Make life better,” Lilly’s acquisition is […]
